Kalydeco 150 MG tablet 56S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRV5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $38,658
Award facts
- Contract value 100% obligated
- $38,657.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $38,657.64 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Kalydeco 150 mg tablets (56-count packages). This firm fixed-price delivery order, issued on January 21, 2026, with an ultimate completion date of January 22, 2026, was awarded without set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $499.9 million contract that positions the company as a critical pharmaceutical supplier for Department of Defense healthcare operations worldwide.
DMS Pharmaceutical Group has established itself as a substantial federal contractor through consistent performance on numerous delivery orders issued by DLA's Medical Supply Chain division since October 2025. The company's extensive product portfolio spans branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and specialty pharmaceuticals supporting diverse therapeutic categories. As part of the broader $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group's contract runs through December 31, 2036, with a 30-month base period and three 30-month option periods, enabling the Defense Logistics Agency to issue firm fixed-price delivery orders for pharmaceutical products to support recurring medical supply needs of military healthcare facilities globally.
Quick answers
Who was awarded contract SPE2DR26FCRV5?
SPE2DR26FCRV5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FCRV5 worth?
The government has obligated $38,658 on SPE2DR26FCRV5.
Is contract SPE2DR26FCRV5 an order under another contract?
Yes. SPE2DR26FCRV5 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRV5 competed?
The extent of competition for SPE2DR26FCRV5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award